Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin-OCD Session Monitors for Protocol HIC: 2000020355
Terence H. W. Ching, Stephen A. Kichuk, Giuliana DePalmer, Christopher Pittenger, Benjamin Kelmendi
October 5, 2022 preprint DOI: 10.31234/osf.io/85s9p (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Double-blind, placebo-controlled study |
|---|---|
| Population | Eligible participants with obsessive-compulsive disorder (OCD) |
| Intervention | Psilocybin |
| Dose | 0.25 mg/kg |
| Topics | Anxiety Psilocybin |
| Keywords | Dosing Obsessive compulsive Context archaeology Exposure therapy Psychotherapist Clinical psychology Pharmacology Hallucinogen |
| Citations | 5 |
| Key points | The study is testing the safety and efficacy of a single 0.25 mg/kg dose of psilocybin with non-directive support for OCD. |
Abstract
The Yale Program for Psychedelic Science (YPPS) is testing the safety and efficacy of psilocybin, administered in conjunction with non-directive psychological support, as a treatment for certain neurological and psychiatric conditions. The study, HIC: 200020355 (Neural correlates of the effects of psilocybin in obsessive-compulsive disorder: A double-blind, placebo-controlled study), will explore the safety and efficacy of a single 0.25 mg/kg dose of psilocybin, administered in a supportive clinical environment, to eligible participants with obsessive-compulsive disorder (OCD). Monitors meet with each participant before, during, and after the dosing session. Monitors do not provide any structured therapy, but rather help participants prepare for the experience of psilocybin dosing, ensure psychological safety during dosing, and provide participants with an unstructured context in which to process their experience during and after dosing at defined timepoints. In doing so, while no structured therapy is provided, the presence and accompaniment by monitors throughout all study sessions may be experienced as supportive or even therapeutic by participants. This manual provides background and details for Monitors on the activities that are required at three points – before, during, and after the dosing session.
Comparable studies
Other randomized controlled trials on psilocybin for anxiety, most cited first.
Citations in the library
Cited by 5
- Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial Frontiers in Psychiatry April 25, 2023
- Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin Combined with Non-Directive Support in the Treatment of OCD March 17, 2023
- A primer for culturally attuned psychedelic clinical trials Journal of Psychedelic Studies May 15, 2025
- The purpose of the psychosocial protocol in the psychedelic-assisted therapy: A scoping review Journal of Psychopharmacology June 26, 2026
- A Primer for Culturally Attuned Psychedelic Research June 3, 2024
Cites 13
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
- Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology December 1, 2011
- Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness Journal of Psychopharmacology September 28, 2011
and 8 more in the library